Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
What's the purpose of the trial?
This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM).
There are 6 centers participating in this trial. Enter a location below to find the closet center.
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!